MRK - Why Is Cancer Focused Adagene Stock Plummeting Today? | Benzinga
Adagene Inc (NASDAQ:ADAG) announced data from its presentation at the American Society of Clinical Oncology 2024 Gastrointestinal Cancers Symposium.
Results come from dose escalation and dose expansion cohorts of ADG126 in combination with Merck & Co Inc (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab) (200 mg/Q3W) evaluating doses from 6 mg/kg to 10 mg/kg in heavily pre-treated advanced/metastatic patients (N=46):
- Limited dose-dependent toxicities were observed.
- Grade 3 TRAEs occurred in 5/46 patients (10.8%), with no Grade 4 or 5 TRAEs and a discontinuation rate of 6.5% (3/46).
- In dose escalation across tumor ...